Pacific Biosciences (PACB) news
Recent news
Pacific Biosciences of California: PacBio expects revenue for the FY2026 to be in the range of $155 million to $165 million
AInvest Wire · Aug 5, 2026Pacific Biosciences of California - expects $30 mln-$40 mln annualized operating expense reduction by end of 2027 - SEC filing
AInvest Wire · Aug 5, 2026PacBio appoints Mark van Oene as president and chief executive officer
Pacific Biosciences of California, Inc. (NASDAQ: PACB) has announced the appointment of Mark Van Oene as Chief Operating Officer, a role that includes oversight of research, development, quality, and manufacturing divisions, as well as strategic planning and corporate development initiatives . Van…
AInvest Wire · Aug 5, 2026Element Biosciences: German court orders Illumina to recall products since March 31, 2023
A German court has issued an order requiring Illumina to recall certain products as of March 31, 2023, following legal proceedings related to its acquisition of Pacific Biosciences. The decision is part of an ongoing regulatory review of Illumina's business practices and market dominance in the…
AInvest Wire · Jul 14, 2026PacBio Appoints Chris Gibson to Board of Directors, Brings AI Expertise in Biology.
• PacBio appoints Chris Gibson to the Board of Directors. • Gibson co-founded and chairs Recursion's Board of Directors. • PacBio develops data tools to maximize HiFi sequencing power. • Gibson brings experience in leveraging AI in biology. • PacBio's Board now strengthened with Gibson's expertise.
AInvest Wire · Mar 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.